{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:32:33Z","timestamp":1785717153135,"version":"3.56.0"},"reference-count":71,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Streptococcus pneumoniae<\/jats:italic> (pneumococcus) remains a significant cause of both mild infections such as otitis media, sinusitis, and bronchitis and more severe manifestations such as bacteremia, pneumonia, and invasive pneumococcal disease. Several key serotypes have been targeted in vaccine development due to their association with increased infectivity. Pneumococcal vaccines are available in two formulations, the unconjugated purified polysaccharide (PPSV) and the conjugated formulation (PCV), which leads to a more robust and prolonged immune response. There have been dramatic reductions in mortality attributed to invasive pneumococcal disease over the past 2 decades due to improved vaccination rates and improved serotype coverage with the existing arsenal of vaccines (PCV13 and PPSV23). Utilizing both conjugate and purified polysaccharide modalities in series has produced greater and lasting immunity. The development of both the PCV15 and the PCV20 vaccines provides an opportunity to use conjugated vaccines against a wider spectrum of pneumococcal serotypes. National guidelines have been updated to incorporate the new pneumococcal vaccines into clinical practice.<\/jats:p>","DOI":"10.1002\/phar.2723","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T06:30:06Z","timestamp":1658730606000},"page":"724-740","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pneumococcal vaccination\u2014A literature review and practice guideline update"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3404-4768","authenticated-orcid":false,"given":"Claudine","family":"El\u2010Beyrouty","sequence":"first","affiliation":[{"name":"Department of Pharmacy Thomas Jefferson University Hospital  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Buckler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Thomas Jefferson University Hospital  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Thomas Jefferson University Hospital  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Thomas Jefferson University Hospital  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-2250","authenticated-orcid":false,"given":"Sara","family":"Groome","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Thomas Jefferson University Hospital  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"issue":"40","key":"e_1_2_9_2_1","first-page":"816","article-title":"Use of 13\u2010valent pneumococcal conjugate vaccine and 23\u2010valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30310-4"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104a1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/518538"},{"key":"e_1_2_9_6_1","unstructured":"Centers for Disease Control and Prevention.Active bacterial core surveillance report emerging infections program network:Streptococcus pneumoniae 2010 (ORIG). Accessed November 30 2021.http:\/\/www.cdc.gov\/abcs\/reports\u2010findings\/survreports\/spneu10\u2010orig.pdf"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/431521"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044113"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1729"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw222"},{"issue":"8","key":"e_1_2_9_11_1","first-page":"1","article-title":"Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices","volume":"46","author":"Nuorti PJ","year":"1997","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"e_1_2_9_12_1","first-page":"CD012306","article-title":"Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children","volume":"2019","author":"Golos M","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/518576"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/313608"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2013.28.1.4"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/499242"},{"key":"e_1_2_9_17_1","unstructured":"PoehlingK KobayashiM.Advisory Committee on Immunization Practices;2020."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051150"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71081-3"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1280"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit800"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6846a5"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/649839"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/651131"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420230051007"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00112-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.08.050"},{"issue":"1","key":"e_1_2_9_28_1","first-page":"CD000422","article-title":"Vaccines for preventing pneumococcal infection in adults","author":"Moberley S","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:EJEP.0000024701.94769.98"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/507340"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1004"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.080734"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu002"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/3.Supplement_1.S31"},{"key":"e_1_2_9_35_1","unstructured":"Prevnar 13 (pneumococcal 13\u2010valent conjugate vaccine). Package insert.Pfizer Inc.;2017."},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/11209330-000000000-00000"},{"issue":"20","key":"e_1_2_9_37_1","first-page":"2364","article-title":"Immunogenicity and safety of a 13\u2010valent pneumococcal conjugate vaccine compared to a 23\u2010valent pneumococcal polysaccharide vaccine in pneumococcal vaccine\u2010na\u00efve adults","volume":"32","author":"Jackson LA","year":"2013","journal-title":"Vaccine"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.010"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.002"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1533777"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.05.031"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00176-12"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000056"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3027"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25502"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"issue":"11","key":"e_1_2_9_47_1","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children \u2013 use of 13\u2010valent pneumococcal conjugate vaccine and 23\u2010valent pneumococcal polysaccharide vaccine \u2013 recommendations of the advisory committee on immunization practices (ACIP)","volume":"59","author":"Nuorti JP","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"25","key":"e_1_2_9_48_1","first-page":"521","article-title":"Use of 13\u2010valent pneumococcal conjugate vaccine and 23\u2010valent pneumococcal polysaccharide vaccine among children aged 6\u201318\u2009years with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP)","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_9_49_1","unstructured":"Vaxneuvance [package insert].Merck & Co Inc.;2021."},{"key":"e_1_2_9_50_1","doi-asserted-by":"crossref","unstructured":"HammittL QuinnD JanczewskaE et al.Phase 3 trial to evaluate safety tolerability and immunogenicity of V114 followed by 23\u2010valent pneumococcal polysaccharide vaccine 6 months later in at\u2010risk adults aged 18\u201349\u2009years (PNEU\u2010DAY). E\u2010Poster presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID);2021.","DOI":"10.1093\/ofid\/ofab466.1244"},{"key":"e_1_2_9_51_1","volume-title":"Safety and Immunogenicity of V114, a 15\u2010Valent Pneumococcal Conjugate Vaccine (PCV), in Adults Infected with Human Immunodeficiency Virus (HIV): A Phase 3 Trial","author":"Mohapi L","year":"2020"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1532250"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.049"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1976581"},{"key":"e_1_2_9_55_1","doi-asserted-by":"crossref","unstructured":"Simon JK StaerkeNB Hemming\u2010HarloM et al.Lot\u2010to\u2010lot consistency safety tolerability and immunogenicity of V114 a 15\u2010valent pneumococcal conjugate vaccine in healthy adults aged \u226550\u2009years: a randomized phase 3 trial (PNEU\u2010TRUE). Poster presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 9\u201312 July 2021.","DOI":"10.1016\/j.vaccine.2021.12.067"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.038"},{"key":"e_1_2_9_57_1","unstructured":"Merck & Co Inc.U.S. FDA accepts for priority review the supplemental biologics license application for Merck's VAXNEUVANCE\u00ae(Pneumococcal 15\u2010valent conjugate vaccine) for use in infants and children [Press release];2021. Accessed December 20 2021.https:\/\/www.merck.com\/news\/u\u2010s\u2010fda\u2010accepts\u2010for\u2010priority\u2010review\u2010the\u2010supplemental\u2010biologics\u2010license\u2010application\u2010for\u2010mercks\u2010vaxneuvance\u2010pneumococcal\u201015\u2010valent\u2010conjugate\u2010vaccine\u2010for\u2010use\u2010in\u2010infants\u2010and\u2010children\/"},{"key":"e_1_2_9_58_1","unstructured":"Merck & Co Inc.Merck announces VAXNEUVANCE\u00ae(Pneumococcal 15\u2010valent conjugate vaccine) met key immunogenicity and safety endpoints in phase 3 pivotal trial evaluating use in infants PNEU\u2010PED (V114\u2010029) [Press release];2021. Accessed December 20 2021.https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck\u2010Announces\u2010VAXNEUVANCE\u2010Pneumococcal\u201015\u2010valent\u2010Conjugate\u2010Vaccine\u2010Met\u2010Key\u2010Immunogenicity\u2010and\u2010Safety\u2010Endpoints\u2010in\u2010Phase\u20103\u2010Pivotal\u2010T\u2010P41MY.pdf"},{"key":"e_1_2_9_59_1","unstructured":"Prevnar 20 (pneumococcal 20\u2010valent conjugate vaccine) [package insert].Wyeth Pharmaceuticals (Pfizer);2021. Accessed December 1 2021.http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=15428"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab375"},{"key":"e_1_2_9_61_1","unstructured":"GierkeR Advisory Committee on Immunization Practices (ACIP).Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage among adults United States.Centers for Disease Control and Prevention (CDC). February 25 2021. Accessed December 3 2021.https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides\u20102021\u201002\/24\u201025\/02\u2010Pneumococcal\u2010Gierke.pdf"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.032"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab990"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.004"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1045"},{"key":"e_1_2_9_66_1","unstructured":"Balfour NCT04887948 Pfizer Jan 12. Accessed January 6 2022.https:\/\/www.europeanpharmaceuticalreview.com\/news\/167524\/promising\u2010results\u2010for\u2010covid\u201019\u2010and\u2010pneumococcal\u2010vaccine\u2010co\u2010administration\/#:~:text=Promising%20results%20for%20COVID\u201019%20and%20pneumococcal%20vaccine%20co\u2010administration \u20107&text=Pfizer%20reveals%20co\u2010administering%20its vaccine%20was%20safe%20and%20immunogenic"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu024"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.051"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2017.08.010"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/60.13.1371"},{"issue":"3","key":"e_1_2_9_71_1","first-page":"302","article-title":"Impact of a pharmacist\u2010led pneumococcal vaccination outreach program in a primary care setting","volume":"5","author":"Goldsworthy J","year":"2022","journal-title":"JACCP"},{"issue":"5","key":"e_1_2_9_72_1","first-page":"488","article-title":"A pharmacy resident\u2010driven pneumococcal vaccination protocol increases vaccination rates in hospitalized patients over 65\u2009years","volume":"2","author":"Wells C","year":"2019","journal-title":"JACCP"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2723","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2723","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:37:49Z","timestamp":1761043069000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/phar.2723"],"URL":"https:\/\/doi.org\/10.1002\/phar.2723","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"2022-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}